Patents by Inventor Cédric BARRIERE

Cédric BARRIERE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
    Publication number: 20210292423
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: January 12, 2021
    Publication date: September 23, 2021
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
    Patent number: 10906978
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: February 2, 2021
    Assignee: SANOFI
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
    Publication number: 20180222987
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: April 2, 2018
    Publication date: August 9, 2018
    Inventors: Jana Albrecht, Cédric Barriere, Christian Beil, Jochen Beninga, Chantal Carrez, Stéphane Guerif, Katja Kroll, Christian Lange, Cendrine Lemoine, Wulf-Dirk Leuschner, Ercole Rao, Marion Schneider, Marie-Cécile Wetzel, Peter Wonerow
  • ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
    Publication number: 20180057597
    Abstract: The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.
    Type: Application
    Filed: July 20, 2017
    Publication date: March 1, 2018
    Inventors: Jana ALBRECHT, Cédric BARRIERE, Christian BEIL, Jochen BENINGA, Chantal CARREZ, Stéphane GUERIF, Katja KROLL, Christian LANGE, Cendrine LEMOINE, Wulf-Dirk LEUSCHNER, Ercole RAO, Marion SCHNEIDER, Marie-Cécile WETZEL, Peter WONEROW
  • SPIRO-OXINDOLE MDM2 ANTAGONISTS
    Publication number: 20140148494
    Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicants: The Regents of the University of Michigan, Sanofi, Ascenta Licensing Corporation
    Inventors: Shaomeng Wang, Yujun Zhao, Wei Sun, Sanjeev Kumar, Lance Leopold, Laurent Debussche, Cedric Barriere, Jean-Christophe Carry, Kwame Amaning
  • SPIRO-OXINDOLE MDM2 ANTAGONISTS
    Publication number: 20120122947
    Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, SANOFI, ASCENTA THERAPEUTICS, INC.
    Inventors: Shaomeng Wang, Yujun Zhao, Wei Sun, Sanjeev Kumar, Lance Leopold, Laurent Debussche, Cedric Barriere, Jean-Christophe Carry, Kwame Amaning